FDA approves Myovant’s oral pill Orgovyx for prostate cancer
This is a new option for advanced prostate cancer patients in the US
The US Food and Drug Administration (FDA) has approved Myovant’s once-daily pill Orgovyx for prostate cancer.
Orgovyx (relugolix), which will become available for advanced prostate cancer patients in the US, offers a new option that enables at-home administration.
This is a particularly attractive option for patients looking to avoid travelling for in-person injections, especially in light of the ongoing COVID-19 pandemic.
“The COVID-19 pandemic has heightened the importance of oral treatments as men with prostate cancer continue to experience difficulties and risks travelling to receive injections,” said Neal Shore, medical director of the Carolina Urologic Research Center and HERO programme steering committee member.